Dabrafenib and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Dabrafenib
Cariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Dabrafenib (Tafinlar) can speed up an enzyme in your body called CYP3A4. That same enzyme handles cariprazine (Vraylar), the medicine that helps with mood or thinking symptoms. Cariprazine also relies on this enzyme to build up its long-acting active forms, so speeding things up could shift how much active medicine you actually have.
Here is the honest part: this specific combination has not been directly studied, so the exact effect is not known. Because of that uncertainty, the two are generally not recommended together. Please don't change anything on your own. Your care team can look at your situation and decide the safest plan, which may include watching your symptoms more closely.
Mechanism: Dabrafenib is a CYP3A4 inducer; cariprazine is a CYP3A4 substrate whose active metabolites (desmethyl- and didesmethyl-cariprazine) are both formed and eliminated via CYP3A4. Neither drug is a prodrug in a way that cleanly reverses interpretation, and because CYP3A4 governs both formation and clearance of the active moieties, the net effect on total active exposure is unpredictable.
- Direction/magnitude: Unclear; not evaluated in studies.
- Evidence: Theoretical.
- Onset: Unspecified (enzyme induction is typically delayed, days to weeks).
- Management: Concurrent use not recommended. If unavoidable, monitor closely for altered efficacy or tolerability and individualize therapy.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
It is advised against giving cariprazine (a substrate of CYP3A4) together with a CYP3A4 inducer. The generation and clearance of cariprazine's active metabolites depend on CYP3A4. How CYP3A4 inducers influence cariprazine exposure has not been studied, so the overall outcome remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
What your care team may do:
- Because the combined effect is uncertain, using these two together is generally not recommended, so your prescriber may consider an alternative.
- If both are needed, your team may monitor you more closely for either reduced benefit or new side effects, and your dose may need to be adjusted and individualized.
What you should do:
- Keep taking both exactly as prescribed unless your doctor tells you otherwise.
- Tell your pharmacist or prescriber that you take both, and report any change in mood, thinking, or side effects.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Dabrafenib and Cariprazine together?
Dabrafenib may unpredictably change how much active cariprazine your body has, so this combination is generally not recommended; talk with your prescriber or pharmacist before making any changes. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Dabrafenib and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Dabrafenib and Cariprazine interaction managed?
What your care team may do: Because the combined effect is uncertain, using these two together is generally not recommended, so your prescriber may consider an alternative. If both are needed, your team may monitor you more closely for either reduced benefit or new side effects, and your dose may need to be adjusted and individualized. What you should do: Keep taking both exactly as prescribed unl… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Dabrafenib or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Dabrafenib
Keep reading about Cariprazine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist